Use of Topical Solasodine of Solanum Melongena Peel Origin in the Treatment of Palmar Arsenic Keratosis
NCT ID: NCT04693000
Last Updated: 2021-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
20 participants
INTERVENTIONAL
2018-09-23
2021-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion
NCT03127670
Identification of Compound From Brinjal Peel Extract in the Treatment of Palmar Arsenical Keratosis and Bowen's Disease
NCT03641079
Effect of the Compound Extracted From Azadirachta Indica Leaves in the Treatment of Arsenical Keratosis
NCT04686474
Effect of Pumpkin Seeds in the Treatment of Moderate to Severe Palmar Arsenical Keratosis
NCT04608461
Effect of Thymoquinone Extracted From Nigella Sativa in the Treatment of Arsenical Keratosis
NCT04686461
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two studies were conducted in the same department where topical ointment prepared from the crude extract of S. melongena peel was found effective in arsenical keratosis.
The present study was conducted to confirm the previous study and identify that solasodine isolated from S. melongena peel is responsible for the cure of the lesions of arsenical keratosis. Thus, it may be possible for the chemical synthesis of solasodine, and an effective, inexpensive topical ointment can be prepared for the cure of arsenical keratosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment
An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.
Keratotic nodular size observation after 12 weeks
Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment
An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Arsenic Keratosis lesion or nodular size observation after 12 weeks of therapy with solasodine ointment
An ointment containing solasodine extract of solanum melongena peel origin applied to patients with palmar arsenical keratosis; dose-twice daily for 12 weeks.Keratotic nodular size observation after 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Drinking arsenic-contaminated water for at least six months
* Patient voluntarily agreed to participate
Exclusion Criteria
* Pregnant and nursing mother
* Skin diseases like atopic dermatitis eczema and psoriasis
* Patient allergic to brinjal (eggplant)
* Patient taken any treatment of arsenicosis for the last six months
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Mohammad Sazzad Hossain
MBBS, MD(Phase B) Resident
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Muradnagar Upazilla
Comilla, , Bangladesh
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BSMMU/2019/10655
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.